Cargando…
Correction: Therapeutic Administration of the Chemokine CXCL1/KC Abrogates Autoimmune Inflammatory Heart Disease
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065052/ http://dx.doi.org/10.1371/journal.pone.0100608 |
Ejemplares similares
-
Therapeutic Administration of the Chemokine CXCL1/KC Abrogates Autoimmune Inflammatory Heart Disease
por: Bachmaier, Kurt, et al.
Publicado: (2014) -
Correction: Interactions of the chemokines CXCL11 and CXCL12 in human tumor cells
por: Koch, Christian, et al.
Publicado: (2023) -
Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine Model
por: Tisato, Veronica, et al.
Publicado: (2014) -
Neuroprotection by inhibiting the c-Jun N-terminal kinase pathway after cerebral ischemia occurs independently of interleukin-6 and keratinocyte-derived chemokine (KC/CXCL1) secretion
por: Benakis, Corinne, et al.
Publicado: (2012) -
Correction to: The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma
por: Ren, Zemin, et al.
Publicado: (2021)